



BIOTECHNOLOGY ANALYST

## DO KIM

Do joined BMO Capital Markets Equity Research in November 2015 as a biotech analyst. For the past five years, Do was a biotech analyst with Nomura Securities, and Piper Jaffray. Do has over 10 years of experience covering the biotech industry.

Do earned an MBA, finance and economics from Columbia University-Columbia Business School, and a B.A. biology from the Johns Hopkins University. Do is a CFA charterholder.

3 Times Square  
29th Floor  
New York, NY 10036

Tel: (212) 885-4091  
Fax: (212) 885-4060  
do.kim@bmo.com

## COVERAGE LIST

Affimed N.V. (AFMD-NSDQ)  
Akcea Therapeutics (AKCA-NSDQ)  
Alnylam Pharmaceuticals (ALNY-NSDQ)  
Amgen (AMGN-NSDQ)  
BioXcel Therapeutics (BTAI-NSDQ)  
Constellation Pharmaceuticals (CNST-NSDQ)  
Fate Therapeutics (FATE-NSDQ)  
Halozyme Therapeutics (HALO-NSDQ)  
Ionis Pharmaceuticals (IONS-OTC)  
Morphic Therapeutic (MORF-NSDQ)  
ObsEva (OBSV-NSDQ)  
Rapt Therapeutics (RAPT-NSDQ)  
Replimune Group (REPL-NSDQ)  
Retrophin (RTRX-NSDQ)  
Rigel Pharmaceuticals (RIGL-NSDQ)  
Scholar Rock (SRRK-NSDQ)  
Schrödinger (SDGR-NSDQ)  
TCR2 Therapeutics (TCRR-NSDQ)  
VBI Vaccines (VBIV-NSDQ)  
Vertex Pharmaceuticals (VRTX-OTC)